1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Oral Session

Start Session

Thumbnail for ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients With Previously Treated CP-CML

CML - 652

ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients With Previously Treated CP-CML

Fadi G Haddad

Poster Presenter: Fadi G Haddad

CLL - 1265

Pirtobrutinib, Venetoclax, and Obinutuzumab Treatment in First-Line CLL (PIVOT-CLL)

Nitin Jain

Poster Presenter: Nitin Jain

Thumbnail for Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

TCL - 418

Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

Tapan Kadia

Poster Presenter: Tapan Kadia

Thumbnail for Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

ABCL - 489

Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

Jason Westin

Poster Presenter: Jason Westin

Video

$Thumbnail for Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): First Real-World Data From the Center for International Blood and Marrow Transplant Research (CIBMTR)$

CT - 230

Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): First Real-World Data From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elise Chong

Poster Presenter: Elise Chong